#United States #Brisbane #cancer screening #Freenome #SimpleScreen CRC

Freenome's Blood-Based Screening Test Included in ACS Guidelines

Freenome, a pioneering company in the early detection of cancer, has recently received significant recognition as its blood-based testing method has been included in the updated American Cancer Society (ACS) guidelines for colorectal cancer screening. This is a substantial advancement in the field of non-invasive cancer detection, where the simplicity of blood tests can greatly enhance patient compliance with screening protocols.

The ACS Updates have introduced a new category specifically for blood-based testing, reflecting a broader shift in cancer screening strategies that prioritize minimally invasive options. SimpleScreen™ CRC, Freenome's flagship test, is currently under review by the FDA, and approval is anticipated by mid-2026. This development is particularly important, considering that many individuals are reluctant to undergo traditional screening methods such as colonoscopies.

Expanding Testing Options

The new guidelines recognize that offering blood-based screening tests can significantly increase participation rates among individuals who may have previously avoided screening due to discomfort or fear associated with invasive procedures. The statement made by the ACS emphasizes that availability of multiple screening options encourages higher adherence among patients, supporting the idea that the most effective screening is the one that is actually completed.

Dr. Aaron Elliott, CEO of Freenome, stated, "Too many eligible individuals remain unscreened for colorectal cancer despite the proven benefits of early detection. The inclusion of blood-based testing in the ACS screening guidelines marks an important step toward expanding patient access to testing." This sentiment reflects a crucial need for solutions that meet patients where they are, thus promoting timely interventions and early treatment.

Clinical Validation and Future Developments

Currently, SimpleScreen CRC has been made available at select pilot sites as a laboratory-developed test (LDT). As the company continues its pursuit of FDA approval, it is also advancing an updated version of SimpleScreen CRC, which includes an independent clinical validation study expected to wrap up in Q3 2026. This follows the preliminary data that was showcased at the 2026 ASCO Gastrointestinal Cancers Symposium.

The collaboration with Abbott, which will spearhead the broad commercialization of SimpleScreen CRC post-approval, highlights the shared commitment to improving colorectal cancer screening and ensuring a future where fewer individuals are left unscreened. As Jake Orville, Senior Vice President of Cancer Diagnostics at Abbott, articulates, expanding colorectal cancer screening necessitates meeting patients with options that truly resonate with their preferences.

Transforming Future Screening Landscapes

Freenome is steadfast in advancing a multi-omics platform that merges artificial intelligence with various biological signals to detect the subtle clues of cancer, even in its earliest stages. Understanding that no single technology can effectively identify every type of cancer is fundamental to their approach, as it aims to cater to the diverse nature of this complex disease.

The incorporation of blood tests in ACS guidelines fosters an environment that is conducive to reaching a larger audience for cancer screenings, and serves as an imperative step towards better health outcomes. Freenome leads this dialogue, seeking to enhance the effectiveness of cancer detection and contribute meaningfully to public health agendas. As these technologies evolve, so too does the hope that the rates of colorectal cancer diagnoses will see favorable trends, ultimately saving more lives through early intervention.

Conclusion

As Freenome continues to push the boundaries of cancer detection technology, the inclusion of its blood test in the ACS guidelines stands as a beacon of progress in the fight against colorectal cancer. With the anticipation of FDA approval and robust marketing strategies, Freenome is set to redefine how patients perceive and engage with screening processes. Greater patient access to effective, non-invasive testing might mean the difference between life and death for many individuals, making this advancement a truly monumental stride forward in cancer care.